Skip to main content
Type at least 3 characters

1,054 articles

Study Protocol

Published on 13 Aug 2024

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)

in Multiple Sclerosis and Neuroimmunology

  • Soon-Tae Lee
  • Hesham Abboud
  • Sarosh R. Irani
  • Hideto Nakajima
  • Amanda L. Piquet
  • Sean J. Pittock
  • E. Ann Yeh
  • Jiawei Wang
  • Sharmila Rajan
  • James Overell
Frontiers in Neurology
doi 10.3389/fneur.2024.1437913
  • 4,740 views
  • 4 citations

Study Protocol

Published on 18 Jul 2024

Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study

in Multiple Sclerosis and Neuroimmunology

  • Giovanna Borriello
  • Clara Grazia Chisari
  • Davide Maimone
  • Massimiliano Mirabella
  • Damiano Paolicelli
  • Francesco Assogna
  • Sandro Caradonna
  • Francesco Patti
Frontiers in Neurology
doi 10.3389/fneur.2024.1422078
  • 2,019 views

Original Research

Published on 27 Jun 2024

Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system

in Multiple Sclerosis and Neuroimmunology

  • Cristina Scavone
  • Antonietta Anatriello
  • Isabella Baccari
  • Andrea Cantone
  • Daniele Di Giulio Cesare
  • Francesca Futura Bernardi
  • Ornella Moreggia
  • Valerio Liguori
  • Vincenzo Andreone
  • Giorgia Teresa Maniscalco
Frontiers in Neurology
doi 10.3389/fneur.2024.1383910
  • 2,454 views